Japan solid dose market predicted to bloom in 201921 Feb 2019
Executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and the second fastest overall country for biologicals growth.
A new report published ahead of CPhI Japan 2019 says tThe Japanese pharma market is expected to grow quickly in 2019.
The trade exhibition (18-20 March, 2019) will open its doors to 20,000 pharma professionals, as industry executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and even more impressively, the second fastest overall country for biologicals growth – finishing only narrowly behind the US.
The findings represent a sizable year-on-year improvement in outlook for pharma in Japan, with expected growth of solid dose formulations improving by more than 10%, with generic drug classes highlighted as offering strong growth prospects. Significantly, it now ranks ahead of all EU nations and Korea – finishing only behind the US of the mature pharma markets.
Laura Murina, Brand Manager CPhI Japan, said: “Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are now observing a dramatic increase in generics and biosimilars in the market.”
The outlook for the biologics sector was even more positive, where growth potential for Japan (7.5) was second only to the US (7.9) – recognising the substantial potential for biosimilars in 2019 and beyond – as a result, the collocated BioPh has become a much larger part of CPhI Japan in recent years.
Japanese companies reported renewed confidence in the domestic market, but more significantly, a larger number are also exploring exports than in previous years. In fact, 2019 will be the first year that Japan’s largest pharma companies gain 50% of their sales from overseas – as recently as 2017 this was still well under 50%, but it has grown quickly in recent years.
Crucially, this internalisation is being observed both ways – inbound and outbound – and is highlighted on the CPhI Japan exhibition floor. In total, more than 20,000 executives will attend, with more than 60 countries represented, and over 550 exhibitors – an increase of over 100 exhibitors in just the last three years alone. These include major suppliers of pharmaceutical ingredients, packaging, contract services, as well as machinery, technology, and new for 2019, digital and IT companies in the Pharma IT & Digital Expo. Another industry segment offering opportunities are nutraceuticals and traditional Chinese medicines (known as Kampo by Japanese consumers). In response, CPhI Japan has launched a new Natural Extracts zone.
The report suggested that the resurgence in international interest is being driven by de-regulation opening up accelerated approval pathways, coupled with one of the world’s fastest-growing generics markets. R&D in Japan also remains at the forefront of global pharma – a result of both the attractiveness of the nation’s medicines market and the strength of local research institutions.
Nobuaki Nito, General Manager UBM Japan, added: “What is most exciting, is that with international collaborations increasing, there are clearly now more partnering opportunities in the market than ever before, which is why it is such a good time to attend CPhI Japan.”
Beyond the exhibition, over 9,000 pharma professionals will attend the CPhI Japan Conference, with insights from The International Federation of Pharmaceutical Manufacturers & Associations（IFPMA), the Japan Pharmaceutical Traders’ Association, as well as industry executives from big pharma, generics and bio. With the government pursuing policies anticipated to grow generics to 80% market share by September 2020, one of the major challenges for the industry will be sourcing a stable supply of APIs and this will form an integral part of the 2019 conference agenda. Other sessions will explore the issues and opportunities for parallel approvals (PMDA alongside FDA or EU) and biosimilar growth strategies.
The report concludes that Japan is a country ripe for growth across a number of product classes, but the long-term winners of regulatory changes, aging demographics and innovative R&D remain hard to pick. What is clear, however, is that the opportunities have widened quickly, and new players would be wise to act fast. In particular, there are renewed opportunities for international contract service providers, generics and finished drug manufacturers as well as domestic manufacturers to become the local manufacturing arms of international firms.
Infinium Pharmachem are Exhibiting at CPHI-Worldwide 2019
17 Jul 2019
The company are exhibiting at CPHI Worldwide in Germany on Nov 5-7 2019.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Piramal expands its high potency API capability
25 Jun 2019
Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
PASCOE Naturmedizin exhibits at CPhI Worldwide Exhibition in Frankfurt
18 Jun 2019
PASCOE Naturmedizin is one of Germany's 100 most innovative medium-sized enterprises. The success story of our family’s specialist naturopathy company began three generations and almost 125 years ago when Friedrich H. Pascoe's first pharmacy in Mülh...Read more
Liquid pharmaceuticals in the digital age
30 May 2019
Inspiration, innovation and technical highlights from Bosch Packaging Technolgy's Pharmatag 2019.Read more
CPhI China opens with analysis pointing to a surge in growth in 2019
28 May 2019
Regulatory reforms and harmonisation reported as key drivers of industry in China.Read more
Expert forecasts huge growth in Middle East manufacturing
16 May 2019
UAE consumers and insurance companies are willing to pay for highest quality drug products.Read more
Lessons learned from early EU FMD adopters
13 May 2019
Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.Read more
Manufacturing growth sees surging demand at CPhI South East Asia
3 May 2019
Number of visitors seeking a contract manufacturer was extremely high, with multinational corporations increasingly looking for local partners to expedite market access into the wider region.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation